The Life Sciences IPOs + Capital Markets team advised Goldman Sachs & Co. LLC and the other underwriters of Ambrx Biopharma’s (NYSE: AMAM) initial public offering on the New York Stock Exchange. Ambrx raised $126 million (USD) in new capital through the issuance of 7 million American Depository Shares (ADS) at a price of USD 18 per ADS.

Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics.

The Goodwin team was led by Robert Puopolo, Seo Salimi, Will Magioncalda, Thomas Schaad, and Peter Rodas (U.S. Corporate) and Wendy Pan and included Alexander Varond and Sarah Wicks (FDA), Olivia Uitto (IP); Roger Cohen, Delphine O’Rourke, and Nik Sethi (Healthcare); Jennifer Fay and Caroline Galiatsos (Employment); Daniel Karelitz and Joshua Lake (Tax); Ettore Santucci (Opinions); and Christopher Haley (Science Advisor); with invaluable assistance from Julie Tibbets and Simone Otenaike.

For more details, read the press release and articles in Seeking Alpha, Endpoints, and MarketWatch.